Roche Removes a Blemish: Drugmaker Drops Its One-Time Acne Blockbuster Accutane

Holding less than 5 percent of isotretinoin market and burdened with the costs of personal injury suits, Roche decides to discontinue its acne drug.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet